“I have at least three more patients in the process of preparing for [a] self-administered fecal transplant at home,” a doctor wrote in 2013. “These patients are highly motivated, know the data on effectiveness, and won’t be told no!”

Backlash was so fierce to the FDA’s suggestion that the agency backed off a month later, saying that it would exercise “enforcement discretion” while working toward a final decision on how to regulate fecal transplants. This essentially gave doctors the go-ahead to keep doing that they’re doing—until something changes.

But now, the newly reported death will likely lead to a clampdown on donors, Kraft told me. The donor for the patient who died was carrying an antibiotic-resistant bacterium called extended-spectrum beta lactamase–producing Escherichia coli, which normally does not sicken healthy people but can be fatal in patients with already weakened immune systems, such as in this recent case.

The role of this bacterium doesn’t come as a huge surprise. OpenBiome, a nonprofit stool bank, already screens for ESBL-producing E. coli along with other antibiotic-resistant bacteria. But individual doctors can still rely on a relative of a patient or find other donors outside of stool banks, and screening practices differ. (OpenBiome did not provide the sample in the fatal case, and the FDA has not made public any further information about the donor or where the procedure was done.)

The FDA is expected to issue its final guidance on fecal transplants very soon. The decision will clear up whether the agency considers fecal transplants to be like drugs; human tissue, such as blood and organs; or an altogether new category of its own.

We want to hear what you think about this article. Submit a letter to the editor or write to letters@theatlantic.com.

Sarah Zhang is a staff writer at The Atlantic.
Categories: Health

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: